Human Vaccines & Immunotherapeutics (Dec 2024)

Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol

  • Narmeen Mallah,
  • Sonia Ares-Gómez,
  • Jacobo Pardo-Seco,
  • Alberto Malvar-Pintos,
  • María-Isolina Santiago-Pérez,
  • Olaia Pérez-Martínez,
  • María-Teresa Otero-Barrós,
  • Nuria Suárez-Gaiche,
  • Rolf Kramer,
  • Jing Jin,
  • Leticia Platero-Alonso,
  • Rosa-María Alvárez-Gil,
  • Olga-María Ces-Ozores,
  • Victoria Nartallo-Penas,
  • Susana Mirás-Carballal,
  • Marta Piñeiro-Sotelo,
  • Juan-Manuel González-Pérez,
  • Carmen Rodríguez-Tenreiro,
  • Irene Rivero-Calle,
  • Antonio Salas,
  • Carmen Durán-Parrondo,
  • Federico Martinón-Torres

DOI
https://doi.org/10.1080/21645515.2024.2348135
Journal volume & issue
Vol. 20, no. 1

Abstract

Read online

ABSTRACTNirsevimab has been recently licensed for universal RSV prophylaxis in infants. NIRSE-GAL is a three-year population-based study initiated in Galicia in September 2023. It aims to evaluate nirsevimab effectiveness against RSV-related hospitalizations lower respiratory tract infections (LRTI), severe RSV, all-cause LRTI, and all-cause hospitalization. NIRSE-GAL also aims to estimate nirsevimab impact on primary healthcare use in the short and mid-term, children’s wheezing and asthma, and medical prescriptions for RSV. The immunization campaigns will be scheduled based on the expected start week for the RSV season and will last the whole season. Immunization will be offered to: i) infants born during the campaign (seasonal), ii) infants < 6 months at the start of the campaign (catch-up), and iii) infants with high-risk factors, aged 6–24 months at the start of the campaign (high-risk). The follow-up period will start: i) the immunization date for all immunized infants, ii) the start of the campaign, for the non-immunized catch-up or high-risk groups, or iii) the birthdate for the non-immunized seasonal group. Infants will be followed up until outcome occurrence, death, or end of study. Nirsevimab effectiveness will be estimated using Poisson and Cox regression models. Sensitivity and stratified analyses will be undertaken. The number of averted cases and the number needed to immunize will be estimated. Immunization failure and nirsevimab safety will be monitored. NIRSE-GAL was approved by the ethics committee of Galicia (CEIC 2023–377) and registered in ClinicalTrials.gov (ID: NCT06180993). Findings will be mainly shared via peer-reviewed publications and scientific conferences.

Keywords